Tarsus Pharmaceuticals, Inc. TARS Indefinite- lived intangible impairment

Indefinite- lived intangible impairment at other companies

AbbVieABBV

——

Bausch + LombBLCO

——

Other financials

Income statement

See full

Revenue$162.1M+107%

Gross profit$152.7M+109%

Operating income-$6.1M+76.7%

Net income-$7.0M+72.3%

EPS (diluted)-$0.16+75.0%

Balance sheet

See full

Cash & equivalents$104.2M-41.6%

Total debt$88.7M+22.5%

Total equity$349.0M+1.9%

Total assets$581.1M+16.1%

Cash flow

See full

Operating cash flow-$24.7M-19.4%

CapEx$5.8M+886%

Free cash flow-$30.5M-43.4%

Valuation

See full

Market cap$2.85B+41.1%

Enterprise value$2.83B+47.8%

P/S5.3×-3.3×

Profitability

See full

Gross margin42.7%—

Operating margin-9.5%-4.2pp

Net margin-9%-4.0pp

FCF margin-28%-12.6pp

Returns & leverage

See full

Return on equity-14%-5.2pp

Debt / equity0.3×0.0×

Current ratio3.7×-1.8×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IntangibleAssetsGrossExcludingGoodwill.

The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tarsus Pharmaceuticals, Inc.'s indefinite- lived intangible impairment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Tarsus Pharmaceuticals, Inc.'s indefinite- lived intangible impairment?: Tarsus Pharmaceuticals, Inc. (TARS) reported indefinite- lived intangible impairment of $9M in Q1 2026.
How has Tarsus Pharmaceuticals, Inc.'s indefinite- lived intangible impairment changed year-over-year?: Tarsus Pharmaceuticals, Inc.'s indefinite- lived intangible impairment decreased by 0.0% year-over-year, from $9M to $9M.